Hojnik Marko, Šuster Nataša Kenda, Smrkolj Špela, Sisinger Damjan, Grazio Snježana Frković, Verdenik Ivan, Rižner Tea Lanišnik
Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
Department of Pathology, University Medical Centre Maribor, 2000 Maribor, Slovenia.
Cancers (Basel). 2022 Feb 5;14(3):809. doi: 10.3390/cancers14030809.
Although aldo-keto reductases (AKRs) have been widely studied in cancer, no study to date has examined the roles of AKR family 1 members B1 (AKR1B1) and B10 (AKR1B10) in a large group of ovarian cancer patients. AKR1B1 and AKR1B10 play a significant role in inflammation and the metabolism of different chemotherapeutics as well as cell differentiation, proliferation, and apoptosis. Due to these functions, we examined the potential of AKR1B1 and AKR1B10 as tissue biomarkers. We assessed the immunohistochemical levels of AKR1B1 and AKR1B10 in tissue paraffin sections from 99 patients with high-grade serous ovarian cancer (HGSC) and compared these levels with clinicopathological characteristics, survival, and response to chemotherapy. A higher immunohistochemical AKR1B1 expression correlated with a better overall and disease-free survival of HGSC patients whereas AKR1B10 expression did not show any significant differences. A multivariant Cox analysis demonstrated that a high AKR1B1 expression was an important prognostic factor for both overall and disease-free survival. However, AKR1B1 and AKR1B10 were not associated with different responses to chemotherapy. Our data suggest that AKR1B1 is involved in the pathogenesis of HGSC and is a potential prognostic biomarker for this cancer.
尽管醛酮还原酶（AKRs）已在癌症领域得到广泛研究，但迄今为止，尚无研究在一大群卵巢癌患者中考察AKR1家族成员B1（AKR1B1）和B10（AKR1B10）的作用。AKR1B1和AKR1B10在炎症、不同化疗药物的代谢以及细胞分化、增殖和凋亡过程中发挥着重要作用。基于这些功能，我们研究了AKR1B1和AKR1B10作为组织生物标志物的潜力。我们评估了99例高级别浆液性卵巢癌（HGSC）患者组织石蜡切片中AKR1B1和AKR1B10的免疫组化水平，并将这些水平与临床病理特征、生存率及化疗反应进行比较。较高的AKR1B1免疫组化表达与HGSC患者更好的总生存期和无病生存期相关，而AKR1B10的表达未显示出任何显著差异。多变量Cox分析表明，高AKR1B1表达是总生存期和无病生存期的重要预后因素。然而，AKR1B1和AKR1B10与不同的化疗反应无关。我们的数据表明，AKR1B1参与了HGSC的发病机制，是这种癌症的潜在预后生物标志物。
